A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.

[1]  S. Mikhail,et al.  Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. , 2015, Journal of hepatology.

[2]  N. Meanwell,et al.  Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase , 2014, Antimicrobial Agents and Chemotherapy.

[3]  D. Nelson,et al.  P1222 A PHASE II STUDY OF SAMATASVIR (IDX719) IN COMBINATION WITH SIMEPREVIR AND RIBAVIRIN IN TREATMENT-NAÏVE HCV-INFECTED SUBJECTS WITH GENOTYPES 1B AND 4 (HELIX-1 STUDY) , 2014 .

[4]  P. Marcellin,et al.  O58 RESULTS FROM THE PHASE 2 PEARL-I STUDY: INTERFERON-FREE REGIMENS OF ABT-450/R + ABT-267 WITH OR WITHOUT RIBAVIRIN IN PATIENTS WITH HCV GENOTYPE 4 INFECTION , 2014 .

[5]  P. Marcellin,et al.  Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. , 2014, Gastroenterology.

[6]  F. Mcphee,et al.  1210 PRE-EXISTENCE, EMERGENCE AND PERSISTENCE OF HCV GENOTYPE 4 NS5A RESISTANCE VARIANTS FROM THE PHASE 2B COMMAND-1 STUDY: DACLATASVIR PLUS PEGINTERFERON-alfa/ RIBAVIRIN IN TREATMENT-NAIVE PATIENTS , 2013 .

[7]  A. Siika,et al.  Hepatitis C virus (HCV) infection in Africa: a review , 2013, The Pan African medical journal.

[8]  F. Sanai,et al.  A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt , 2011, Liver international : official journal of the International Association for the Study of the Liver.